Immix Biopharma Announces Pricing of $150 Million Common Stock Offering

On May 21, 2026, Immix Biopharma, Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC to sell 16,778,524 shares of its common stock in an underwritten public offering. The shares are priced at $8.94 per share, with the offering expected to generate gross proceeds of approximately $150 million. After deducting underwriting discounts, commissions, and estimated offering expenses, the company expects to receive net proceeds of approximately $140.65 million. The offering is conducted under an existing shelf registration statement and is scheduled to close on May 22, 2026, subject to customary closing conditions. In connection with the offering, certain officers and directors of the company have entered into lock-up agreements restricting the sale of common stock for a specified period. The company intends to use the net proceeds for general corporate purposes, which may include research and development, clinical trials, and working capital. Immix Biopharma continues to qualify as an emerging growth company under the Securities Act.